Also found in: Wikipedia.
ASTEXAtlantic Stratocumulus Transition Experiment
ASTEXAdvanced Space Technology Experiment
References in periodicals archive ?
50 per Astex share, representing a 48 per cent premium on the average closing price over the previous 30 days, has the backing of both company boards and comes just a little over two years after US firm, Supergen, merged with Cambridges Astex Therapeutics to create Astex Pharmaceuticals, a deal that then valued the Cambridge company at around $120m.
Shortly after we released our letter, Astex issued an open letter, apparently to respond to our and other shareholders' concerns about the current transaction.
AT7519 and AT13148 are among five compounds currently being developed by Astex for the treatment of solid tumours and haematological malignancies.
The Company expanded its product pipeline following the Astex acquisition to include four company-sponsored phase II programs and four partner-sponsored clinical programs.
We believe the recently announced merger transaction with Otsuka Pharmaceutical significantly undervalues Astex and therefore we do not intend to tender our shares.
Contacts: Astex Therapeutics Limited, Leon Bushara, Chief Executive Officer, Email: l.
The coming months and years will be exciting ones at Astex as we continue to evolve into a fully-integrated drug discovery and development company, with a growing number of products advancing toward the market.
Astex has been actively involved in human cytochrome P450 research since the company's formation and Astex scientists were the first group to successfully solve the crystal structures of human cytochromes P450, 3A4 and 2C9(3).
The decision to transfer the CLIMB[TM] epigenetic program to GSK was based on our assessment of internal resources and discussions with GSK," said Harren Jhoti, PhD, president of Astex Pharmaceuticals.
Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), AstraZeneca PLC (NYSE: AZN), Astex Pharmaceuticals, Inc.
Astex Therapeutics today announced that it had begun dosing first patients in a Phase I/IIa clinical trial of its investigational anti-cancer drug AT9283.